Friday, September 16, 2022 10:00:48 PM
CRT's stock is down on heavy volume as a blog post from the husband of treated
Patient #2 reported that she has stopped therapy due to a mutation
(https://www.givesendgo.com/Woldt). While social media post are not company
press releases and in the vast majority of situations must be taken with a grain of
salt, there appears to be some validity here. With data from the objective response
(OR) seen in Patient #1 - who has lung cancer - about to be presented on
September 30, we are buyers of TCRT here on weakness. BUY.
Details from GoFundMe Blog
Now all of this from the unsolicited blog/link above. The woman has advanced
colon cancer which was targeted with P53 mutation from the TCR-T Library. She
started treatment late-Spring/early Summer that initially resulted in a 27% tumor
reduction. The mutation appears to have occurred after recent blood work was
performed at MD Andersen. A mutation in colon cancer is not unheard of as colon
cancer is known to often mutate when under pressure, i.e. chemotherapy.
Importantly and despite the setback in treatment, the patient is healthy enough to
resume chemotherapy and did not appear to suffer any platform-related side
effects that might have a negative read through to TCRT. Hence is the beauty of
the Alaunos' Sleeping Beauty kill switch and stopping the overactive immune
response before it gets out of control. As a reminder, all of this is unconfirmed
although the blog and its details appear legit.
Patient #1 Is Key
Most importantly, Alaunos recently confirmed that it has seen an objective partial
response (OR) in the first patient treated in the study. Patient #1 has non-small c
lung cancer, and had one prior line of adjuvant therapy following surgery and thre
prior lines of systemic therapy. The patient has a tumor with a KRAS G12D
mutation, not P53. The patient was treated at the first dose level with TCR-T cells.
an objective response was observed and has now cleared the 28-day safety
window. TCRT will report initial data from the study on Friday, September 30,
8:30am ET at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy
Conference.
A LOT MORE TO COME
In our view, the TCR-T platform has the ability to treat solid tumors with CAR-T
therapy, and the setback with Patient #2 will be a learning event for the Company.
The proprietary safety kill switch is a life saver in immuno-oncology. With only two
very late-stage patients having been treated, a 50% overall response rate (ORR)
would be more than acceptable.
The Company is advancing it's TCR-T Library Phase 1/2 trial targeting KRAS,
TP53 and EGFR mutations across six solid tumor indications, obviously the first
being lung, the second colorectal. We expect the upcoming detailed data from
Patient #1 will be positive and help the stock to regain its momentum. As we know
that different tumors respond differently and this is a very small sample size we are
dealing with; hence, the wild volatility in TCRT shares. However, we know for sure
that the platform has resulted in at least one objective response in a very advanced
lung cancer patient at the first dose, and that patient has been cleared by the FDA
to advance to the next dose. We are buyers on this weakness.
Recent TCRT News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 02:46:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:44:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:05:27 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:43:20 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:58:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:45:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:47:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:30:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:30:50 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:25:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 01:00:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 01:00:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 12:30:01 PM
- Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives • GlobeNewswire Inc. • 11/14/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 08:01:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2023 09:34:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/01/2023 04:20:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:37:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:16:29 PM
- Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives • GlobeNewswire Inc. • 08/14/2023 08:05:34 PM
- Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies • GlobeNewswire Inc. • 06/29/2023 11:00:53 AM
- Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting • GlobeNewswire Inc. • 05/25/2023 09:00:52 PM
- Alaunos Therapeutics Reports First Quarter 2023 Financial Results • GlobeNewswire Inc. • 05/10/2023 11:00:17 AM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM